Pharma solutions
Lipidor develops pharmaceuticals for skin with unique lipid based formulation opportunities for global pharma companies. Our proprietary delivery platform and expertise help pharma companies launch innovative, patient-friendly skin treatments, in record time.
Introduction
Our innovative and flexible delivery system AKVANO® brings a number of tangible benefits for pharmaceutical companies and patients alike.
Our focus is to reformulate existing generika to new, innovative candidates using our proprietary delivery platform AKVANO®. Reformulating existing substances enables a faster track through clinical trials to regulatory approval – and together with our clients – commercial launch.
The flexibility of the AKVANO® platform has enabled us to successfully incorporate more than 60 structurally very different active pharmaceutical ingredients, used in many different therapeutic applications. Applications such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anaesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema and anti-migraine.
Ease of use
AKVANO® formulations provide excellent cosmetic qualities, are quick and simple to use and dry quickly, leaving a pleasant feeling to the skin. Being inherently non-greasy and non-sticky means they can be worn comfortably under clothes without staining them.
Non-touch application
AKVANO® formulations allow non-touch application for sensitive skin. Non-touch application also minimises irritation for sensitive skin.
Reduced irritation
AKVANO® formulations do not require preservatives or additional components that may cause skin irritation. Furthermore, AKVANO® formulations reinforce the skin barrier function which render the skin less susceptible for irritation.
Increased patient compliance
The positive properties of AKVANO® mean it has the potential to increase compliance rates – leading to better efficacy outcomes, and increasing the willingness of physicians to prescribe the treatment to new patients.
Company
Lipidor is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in pre-clinical and clinical phases.
Lipidor update
I hope you have all had a wonderful summer!
Lipidor’s focus is on advancing our drug candidate for psoriasis, AKP02G2, through a Phase III study. This drug candidate is a so-called supergeneric, in the form of a fast-drying spray, which we are confident will provide significant patient benefits. We are very pleased that the raising of capital in the second quarter went well, and the company is now funded to conduct the clinical trial with AKP02G2.
Business scope
The global demand for pharmaceuticals for skin is a large and growing market. With the revolutionary AKVANO® delivery platform, Lipidor is at the cutting-edge of innovation. Want to know more?